Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (36)	10/1/2002 12:13:13 AM
From: mopgcw	Read Replies (1) \| Respond to of 276

Illumina Receives $9 Million from the National Institutes of Health for Large-Scale Genotyping of the Human Genome Businesswire, Monday, September 30, 2002 at 18:10 SAN DIEGO, Sep 30, 2002 (BUSINESS WIRE) -- Illumina, Inc. (Nasdaq:ILMN) announced today that it has been awarded $9 million from the National Institutes of Health (NIH) for large-scale genotyping aimed at understanding the widespread genetic variations that predispose individuals to common illnesses such as cancer and Alzheimer's disease. The award follows completion of a $1 million SBIR grant from the NHGRI to develop BeadArray(TM) technology for large-scale genotyping, which contributed to the introduction of a SNP-based linkage panel and the launch of an integrated, high-throughput genotyping system. The linkage panel and highly scalable genotyping system, announced in June 2002 and July 2002, respectively, currently achieve assay multiplexing levels over 1,000 and genotyping capacity in excess of 1,000,000 genotypes per day, demonstrating the industry-leading performance of the BeadArray genotyping platform. According to Jay Flatley, Illumina President and CEO,"We're both gratified and proud that the NIH has come to Illumina, and to our Scientific Operations and Oligator(TM) oligonucleotide teams, which will leverage our BeadArray platform and Oligator technology, to perform the extensive services required for Illumina's project deliverables. The high throughput and low genotyping cost of our BeadArray technology has already allowed us to win and deliver on genotyping contracts from a wide range of customers."Mark Chee, Ph.D., Illumina Research Fellow and Principal Investigator for the project, commented,"We look forward to participating in NIH studies that strive to decipher the human genome and identify the genetic basis of common diseases."Illumina (Nasdaq: ILMN)(www.illumina.com) is developing next-generation tools that will permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology can provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine."